Conclusion
Molecular screening plays an important role in diagnosing LTBI and reactivation TB. However, careful understanding of the mechanism behind these molecular tests, as well as thorough interview/chart review is important to effectively diagnose and treat TB in immunocompromised patients. Detection protocols should use TST, IGRA and chest imaging to increase sensitivity, as well as MCT-PCR to rule out active disease in patients with high clinical suspicion. Furthermore, TB protocols in immunocompromised patients with high clinical suspicion should include airborne isolation and prophylaxis at presentation, even with negative IGRA.